Biocon receives regulatory approval for biosimilar product, trastuzumab

[News]

Mylan Inc. today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product.

More... (http://www.news-medical.net/news/20131126/Biocon-receives-regulatory-approval-for-biosimilar-product-trastuzumab.aspx)